GLOBALT Investments LLC GA bought a new stake in Edwards Lifesciences Co. (NYSE:EW – Free Report ) during the fourth quarter, according to the latest 13F filing with the SEC. The institutional investor purchased 12,387 shares of the medical research company’s stock worth roughly $945,000.
A number of other hedge funds are also buying and selling shares of EW. DSM Capital Partners LLC acquired a stake in Edwards Lifesciences worth about $28,000 in the fourth quarter. Turtle Creek Wealth Advisors LLC acquired a stake in Edwards Lifesciences worth $34,000 in the fourth quarter. Pingora Partners LLC acquired a stake in Edwards Lifesciences worth $38,000 in the fourth quarter. Operose Advisors LLC increased its stake in Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock, valued at $44,000, after acquiring an additional 452 shares during the period. Finally, SRS Capital Advisors Inc. increased its stake in Edwards Lifesciences by 292.6% in the third quarter. SRS Capital Advisors now owns 636 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 474 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.
Insiders bet
In other news, Vice President, Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total value of $1,212,624.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The transaction was disclosed in a legal filing with the Securities and Exchange Commission, which is available at this hyperlink. In other news, CFO, Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95.Following the sale, the Chief Financial Officer now directly owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The transaction was disclosed in a legal filing with the Securities and Exchange Commission, available at this link. Additionally, Vice President, Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction that took place on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction value of $1,212,624.00. Following the sale, the Vice President now directly owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 127,104 shares of the company’s stock, valued at $11,267,464. Company insiders own 1.29% of the company’s shares.
Analyst Rating Changes
EW has been the topic of numerous research reports. Barclays increased their price objective on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 7th. Morgan Stanley raised their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Finally, Piper Sandler boosted their price objective on Edwards Lifesciences from $85.00 to $88.00 and rated the stock “neutral” in a report on Friday, April 26. One analyst has rated the stock with a sell rating, five have rated it with a hold rating, and fifteen have rated it with a buy rating. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of a “moderate buy” and a consensus target price of $95.06.
Check out the latest research report on EW
Edwards Lifesciences Stock Performance
NYSE:EW opened trading at $87.29 on Friday. The company’s 50-day moving average price is $87.76 and its 200-day moving average price is $83.71. The company’s current ratio is 3.75, quick ratio is 2.67 and debt-to-equity ratio is 0.08. The company has a market cap of $52.6 billion, a P/E ratio of 37.63, a P/G ratio of 3.21 and a beta of 1.11. Edwards Lifesciences Inc.’s low in the past 12 months is $60.57 and its high in the past 12 months is $96.12.
Edwards Lifesciences (NYSE:EW – get free report ) announced its latest earnings results on Thursday, April 25th. The medical research company reported quarterly EPS of $0.66, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had net margins of 23.01% and return on equity of 22.86%. The company’s quarterly revenue of $1.60 billion beat the consensus estimate of $1.58 billion. On average, sell-side analysts expect Edwards Lifesciences to post EPS of $2.77 for the current quarter.
Edwards Lifesciences Profile
(Free report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan and worldwide. The company offers transcatheter heart valve replacement products for minimally invasive replacement of the aortic valve under the Edwards SAPIEN Valve System family, as well as transcatheter heart valve repair and replacement products for the treatment of mitral and tricuspid valve disease under the PASCAL PRECISION and Cardioband names.
read more
Want to see if other hedge funds hold EW? Visit HoldingsChannel.com to get the latest 13F filings and insider transactions for Edwards Lifesciences Co. (NYSE:EW – Free Report).
Receive Edwards Lifesciences news and reviews daily –Enter your email address below to receive a concise summary of the latest news and analyst ratings on Edwards Lifesciences and related companies every day with MarketBeat.com’s free email newsletter.
